195
Views
7
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Impact of atrial fibrillation on levels of high-sensitivity troponin I in a 75-year-old population

, , , , , & show all
Pages 308-313 | Received 16 Sep 2014, Accepted 18 Jan 2015, Published online: 12 Mar 2015

References

  • Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28:973–7.
  • Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946–52.
  • Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med 2013;274:461–8.
  • Tveit A, Abdelnoor M, Enger S, Smith P. Atrial fibrillation and antithrombotic therapy in a 75-year-old population. Cardiology 2008;109:258–62.
  • Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J 2013;34:1475–80.
  • Tveit A SI, Grundvold I, Abdelnoor M, Smith P, Arnesen H. Effect of candesartan and various inflammation markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol 2007;99:1544–8.
  • Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H. Levels of PAI-1 and outcome after electrical cardioversion for atrial fibrillation. Thromb Res 2008; 121:447–53.
  • Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Arnesen H, Smith P. Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion. Int J Cardiol 2009; 131:234–9.
  • Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012; 58:1574–81.
  • Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Rosjo H, Saltyte Benth J, Maggioni A, Domanski MJ, Rouleau JL, Sabatine MS, Braunwald E. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol 2013;61:1240–9.
  • White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol 2011;57:2406–8.
  • Rubini Gimenez M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Schaefer M, Zellweger C, Moehring B, Stallone F, Sou SM, Mueller M, Denhaerynck K, Mosimann T, Reiter M, Meller B, Freese M, Stelzig C, Klimmeck I, Voegele J, Hartmann B, Rentsch K, Osswald S, Mueller C. Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. Eur Heart J 2014;35:2303–11.
  • Eggers KM, Lind L, Ahlstrom H, Bjerner T, Ebeling Barbier C, Larsson A, Venge P, Lindahl B. Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur Heart J 2008;29:2252–8.
  • Eggers KM, Venge P, Lindahl B, Lind L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J Am Coll Cardiol 2013;61:1906–13.
  • Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 2012;125:1605–16.
  • Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, Gersh BJ, Mohan P, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2014;129:625–34.
  • Rienstra M, Yin X, Larson MG, Fontes JD, Magnani JW, McManus DD, McCabe EL, Coglianese EE, Amponsah M, Ho JE, Januzzi JL Jr, Wollert KC, Fradley MG, Vasan RS, Ellinor PT, Wang TJ, Benjamin EJ. Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation. Am Heart J 2014; 167:109–15.e2.
  • Gupta K, Pillarisetti J, Biria M, Pescetto M, Abu-Salah TM, Annapureddy C, Ryschon K, Dawn B, Lakkireddy D. Clinical utility and prognostic significance of measuring troponin I levels in patients presenting to the emergency room with atrial fibrillation. Clin Cardiol 2014;37:343–9.
  • Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart 2014;100:1193–200.
  • Collinson PO, Heung YM, Gaze D, Boa F, Senior R, Christenson R, Apple FS. Influence of population selection on the 99th percentile reference value for cardiac troponin assays. Clin Chem 2012;58:219–25.
  • Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol 2002;40:2065–71.
  • Venge P, Johnston N, Lindahl B, James S. Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol 2009;54:1165–72.
  • Lippi G. The mystifying nomenclature of cardiac troponin immunoassays. Scand J Clin Lab Invest 2014;74:273–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.